The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary

6Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Background Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012. The present study aimed to assess the effectiveness, safety profile, and persistence to fingolimod in a real-life setting in Hungary in RRMS patients who were either therapy naïve before enrollment or have changed to fingolimod from another disease-modifying therapy (DMT) for any reason. Methods This cross-sectional, observational study with prospective data collection was performed nationwide at 21 sites across Hungary. To avoid selection bias, sites were asked to document eligible patients in consecutive chronological order. Demographic, clinical, safety and efficacy data were analysed for up to 5 years from 570 consenting adult patients with RRMS who had received treatment with fingolimod for at least one year. Results 69.6% of patients remained free from relapses for the whole study duration; in the first year, 85.1% of patients did not experience a relapse, which rose to 94.6% seen in the 5th year. Compared to baseline at study end, 28.2% had higher, and 9.1% had lower, meanwhile, 62.7% of the patients had stable EDSS scores. Overall, the annualized relapse rate decreased from 0.804 observed at baseline to 0.185, 0.149, 0.122, 0.091, and 0.097 (77.0%, 82.1%, 85.2%, 89.7%, and 89.0% relative reduction, respectively) after 1, 2, 3, 4, and 5 years of treatment. The greatest reduction rate was seen in the group of therapy naïve patients. Treatment persistence on fingolimod after 60 months was 73.4%. Conclusion In this nationwide Hungarian cohort, most patients under fingolimod treatment were free from relapses and disability progression. In addition, fingolimod has proven to be a well-tolerated DMT that has sustained its manageable safety profile, high efficacy, and positive benefit/risk ratio for up to 5 years in a real-life setting.

References Powered by Scopus

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

13518Citations
N/AReaders
Get full text

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

2313Citations
N/AReaders
Get full text

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1975Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis

9Citations
N/AReaders
Get full text

Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis

7Citations
N/AReaders
Get full text

Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Biernacki, T., Sandi, D., Füvesi, J., Fricska-Nagy, Z., Kincses, T. Z., Ács, P., … Bencsik, K. (2022). The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLoS ONE, 17(4 April). https://doi.org/10.1371/journal.pone.0267346

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

83%

Researcher 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

43%

Nursing and Health Professions 2

29%

Neuroscience 1

14%

Veterinary Science and Veterinary Medic... 1

14%

Save time finding and organizing research with Mendeley

Sign up for free